Haverford Trust Co Has $86.68 Million Position in Stryker Corporation $SYK

Key Points

• Haverford Trust Co increased its investment in Stryker Corporation to $86.68 million, owning 232,846 shares after a purchase of 18,292 shares in the first quarter.
• A significant institutional investor, GAMMA Investing LLC, raised its stake in Stryker by an astounding 43,226.8%, now holding over 2 million shares valued at approximately $772 million.
• Stryker reported a quarterly revenue of $6.02 billion, exceeding analysts' expectations, and announced a quarterly dividend of $0.84, yielding 0.9% annually.

Haverford Trust Co boosted its position in shares of Stryker Corporation (NYSE:SYK - Free Report) by 8.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 232,846 shares of the medical technology company's stock after purchasing an additional 18,292 shares during the quarter. Haverford Trust Co owned 0.06% of Stryker worth $86,677,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SYK. GAMMA Investing LLC lifted its stake in Stryker by 43,226.8% in the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after buying an additional 2,070,133 shares in the last quarter. Nuveen LLC bought a new position in Stryker in the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company's stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Stryker in the fourth quarter valued at approximately $154,140,000. Finally, Northern Trust Corp lifted its stake in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock valued at $1,298,426,000 after buying an additional 420,153 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Truist Financial set a $415.00 price target on shares of Stryker and gave the company a "hold" rating in a research note on Monday, August 4th. Sanford C. Bernstein set a $450.00 target price on shares of Stryker in a report on Monday, May 5th. Finally, Evercore ISI increased their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Stock Performance

Shares of SYK stock opened at $393.8040 on Friday. The stock has a market cap of $150.56 billion, a P/E ratio of 52.16, a P/E/G ratio of 2.80 and a beta of 0.91. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company has a fifty day moving average price of $387.51 and a two-hundred day moving average price of $379.50. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is currently 44.50%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.